Core Insights - Guangdong Taiankang Pharmaceutical Co., Ltd. announced a significant breakthrough with its subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. receiving a drug registration certificate for Finasteride and Tadalafil capsules, branded as Aitinglie, making it the first company in China to obtain approval for this medication [1][2] - The combination drug exhibits unique multi-target therapeutic advantages for treating benign prostatic hyperplasia (BPH), containing 5mg of Finasteride and 5mg of Tadalafil, addressing different pathological mechanisms of BPH [1] Company Developments - The approval of Aitinglie fills a market gap for combination therapies for BPH in China, as the drug was previously developed by the U.S. company VERU and approved by the FDA in December 2021 [2] - Taiankang plans to launch Aitinglie in the first quarter of next year, which is expected to significantly contribute to the company's performance and enhance its product portfolio in the urology and geriatric treatment sectors [2] - The new drug approval strengthens the company's research and industrialization capabilities in chemical pharmaceuticals, injecting new growth momentum and improving its core competitiveness and market influence [2]
泰恩康创新复方制剂“爱廷列”非那雄胺他达拉非胶囊获批